vs

Side-by-side financial comparison of ALLIANCE ENTERTAINMENT HOLDING CORP (AENT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $368.7M, roughly 1.7× ALLIANCE ENTERTAINMENT HOLDING CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.5%, a 31.9% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -6.3%). Over the past eight quarters, ALLIANCE ENTERTAINMENT HOLDING CORP's revenue compounded faster (32.1% CAGR vs 4.6%).

Alliance Atlantis Communications Inc. was a media company that operated primarily as a specialty service provider in Canada. Primarily based in Toronto, Alliance Atlantis also had offices in Halifax, Los Angeles, London, Dublin, Madrid, Barcelona, Shannon, and Sydney.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

AENT vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.7× larger
RPRX
$622.0M
$368.7M
AENT
Growing faster (revenue YoY)
RPRX
RPRX
+11.1% gap
RPRX
4.8%
-6.3%
AENT
Higher net margin
RPRX
RPRX
31.9% more per $
RPRX
34.4%
2.5%
AENT
Faster 2-yr revenue CAGR
AENT
AENT
Annualised
AENT
32.1%
4.6%
RPRX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AENT
AENT
RPRX
RPRX
Revenue
$368.7M
$622.0M
Net Profit
$9.4M
$214.2M
Gross Margin
Operating Margin
4.7%
62.4%
Net Margin
2.5%
34.4%
Revenue YoY
-6.3%
4.8%
Net Profit YoY
32.8%
2.9%
EPS (diluted)
$0.18
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AENT
AENT
RPRX
RPRX
Q4 25
$368.7M
$622.0M
Q3 25
$254.0M
$609.3M
Q2 25
$227.8M
$578.7M
Q1 25
$213.0M
$568.2M
Q4 24
$393.7M
$593.6M
Q3 24
$229.0M
$564.7M
Q2 24
$236.9M
$537.3M
Q1 24
$211.2M
$568.0M
Net Profit
AENT
AENT
RPRX
RPRX
Q4 25
$9.4M
$214.2M
Q3 25
$4.9M
$288.2M
Q2 25
$5.8M
$30.2M
Q1 25
$1.9M
$238.3M
Q4 24
$7.1M
$208.2M
Q3 24
$397.0K
$544.0M
Q2 24
$2.5M
$102.0M
Q1 24
$-3.4M
$4.8M
Operating Margin
AENT
AENT
RPRX
RPRX
Q4 25
4.7%
62.4%
Q3 25
4.2%
70.1%
Q2 25
4.3%
36.3%
Q1 25
1.7%
94.0%
Q4 24
3.8%
60.9%
Q3 24
0.9%
Q2 24
0.2%
50.2%
Q1 24
-0.3%
-13.0%
Net Margin
AENT
AENT
RPRX
RPRX
Q4 25
2.5%
34.4%
Q3 25
1.9%
47.3%
Q2 25
2.5%
5.2%
Q1 25
0.9%
41.9%
Q4 24
1.8%
35.1%
Q3 24
0.2%
96.3%
Q2 24
1.1%
19.0%
Q1 24
-1.6%
0.8%
EPS (diluted)
AENT
AENT
RPRX
RPRX
Q4 25
$0.18
$0.49
Q3 25
$0.10
$0.67
Q2 25
$0.11
$0.07
Q1 25
$0.04
$0.55
Q4 24
$0.14
$0.46
Q3 24
$0.01
$1.21
Q2 24
$0.05
$0.23
Q1 24
$-0.07
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AENT
AENT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$117.6M
$9.7B
Total Assets
$434.1M
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AENT
AENT
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
Q3 24
$4.3M
$950.1M
Q2 24
$1.1M
$1.8B
Q1 24
$1.6M
$843.0M
Total Debt
AENT
AENT
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
AENT
AENT
RPRX
RPRX
Q4 25
$117.6M
$9.7B
Q3 25
$108.1M
$9.6B
Q2 25
$103.2M
$9.5B
Q1 25
$97.4M
$9.8B
Q4 24
$95.6M
$10.3B
Q3 24
$88.0M
$10.3B
Q2 24
$87.6M
$9.8B
Q1 24
$85.1M
$9.9B
Total Assets
AENT
AENT
RPRX
RPRX
Q4 25
$434.1M
$19.6B
Q3 25
$383.0M
$19.3B
Q2 25
$361.2M
$18.3B
Q1 25
$349.4M
$17.6B
Q4 24
$401.7M
$18.2B
Q3 24
$395.7M
$18.0B
Q2 24
$340.8M
$17.7B
Q1 24
$324.0M
$16.1B
Debt / Equity
AENT
AENT
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AENT
AENT
RPRX
RPRX
Operating Cash FlowLast quarter
$-16.5M
$827.1M
Free Cash FlowOCF − Capex
$-16.9M
FCF MarginFCF / Revenue
-4.6%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-1.76×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$-1.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AENT
AENT
RPRX
RPRX
Q4 25
$-16.5M
$827.1M
Q3 25
$2.7M
$702.6M
Q2 25
$10.7M
$364.0M
Q1 25
$2.5M
$596.1M
Q4 24
$25.3M
$742.5M
Q3 24
$-11.6M
$703.6M
Q2 24
$9.7M
$658.2M
Q1 24
$20.0M
$664.6M
Free Cash Flow
AENT
AENT
RPRX
RPRX
Q4 25
$-16.9M
Q3 25
$2.4M
Q2 25
$10.7M
Q1 25
$2.4M
Q4 24
Q3 24
$-11.6M
Q2 24
Q1 24
$20.0M
FCF Margin
AENT
AENT
RPRX
RPRX
Q4 25
-4.6%
Q3 25
0.9%
Q2 25
4.7%
Q1 25
1.1%
Q4 24
Q3 24
-5.1%
Q2 24
Q1 24
9.4%
Capex Intensity
AENT
AENT
RPRX
RPRX
Q4 25
0.1%
Q3 25
0.1%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
Q1 24
0.0%
Cash Conversion
AENT
AENT
RPRX
RPRX
Q4 25
-1.76×
3.86×
Q3 25
0.56×
2.44×
Q2 25
1.86×
12.06×
Q1 25
1.33×
2.50×
Q4 24
3.57×
3.57×
Q3 24
-29.31×
1.29×
Q2 24
3.85×
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AENT
AENT

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons